Brokerages Set Immatics N.V. (NASDAQ:IMTX) Price Target at $14.67

Immatics N.V. (NASDAQ:IMTX) has earned an average recommendation of “Buy” from the five research firms that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.6667.

Several research analysts have weighed in on IMTX shares. Deutsche Bank Aktiengesellschaft started coverage on Immatics in a research report on Wednesday, May 28th. They issued a “buy” rating and a $10.00 price objective on the stock. Wall Street Zen cut Immatics from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 22nd.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMTX. Guggenheim Capital LLC purchased a new position in shares of Immatics during the 4th quarter valued at $101,000. Wasatch Advisors LP raised its stake in shares of Immatics by 9.7% during the 4th quarter. Wasatch Advisors LP now owns 957,052 shares of the company’s stock valued at $6,805,000 after purchasing an additional 84,541 shares during the period. Marshall Wace LLP bought a new stake in shares of Immatics during the 4th quarter valued at $409,000. T. Rowe Price Investment Management Inc. raised its stake in shares of Immatics by 43.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company’s stock valued at $75,400,000 after purchasing an additional 3,225,141 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after purchasing an additional 2,479 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Trading Up 7.3%

IMTX stock opened at $6.33 on Monday. The stock’s fifty day simple moving average is $6.03 and its two-hundred day simple moving average is $5.20. Immatics has a 1-year low of $3.30 and a 1-year high of $13.09. The stock has a market cap of $769.41 million, a P/E ratio of -9.74 and a beta of 0.93.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%. The business had revenue of $6.48 million during the quarter, compared to analysts’ expectations of $13.05 million. As a group, analysts forecast that Immatics will post -0.72 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.